

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal

全部 图片 视频 新闻 地图 图书

找到约 113,000 条结果

时间不限

过去 1 小时内
过去 24 小时内
过去 1 周内
过去 1 个月内
过去 1 年内

所有结果

精确匹配

Google 学术: Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.

... biomarkers in resected colon cancer: current status and ... - Tejpar - 被引用次数: 133

... prognostic and predictive markers in colorectal cancer - Walther - 被引用次数: 540

... diagnosis, prognosis and treatment of colorectal cancer - Coppède - 被引用次数: 81

Integrating anti-EGFR therapies in metastatic colorectal cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712294/>

13 May 2013 ... About 20% of patients present with metastatic colorectal cancer (mCRC) and untreated, ... for mutations in KRAS, BRAF and PIK3CA by direct sequencing as well as EGFR ... The KRAS mutation testing became a NCCN recommendation in November 2008 (19). ... Maughan TS, Adams RA, Smith CG, et al.

Mutation profiling in chinese patients with metastatic colorectal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053731/>

1 Apr 2016 ... KRAS, NRAS, BRAF and PIK3CA mutations had association with ... Keywords: colorectal cancer, mutation profile, RAS mutations, OncoCarta™ Panel, Chinese ... The results of mutation frequency with more than 5% integrated with ... Chan KF, Chan TS, Tsui WM, Tsang AK, Fung MN, Chan AT, To KF.

Biomarker Use in Colorectal Cancer Therapy - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696980/>

KRAS mutational analysis for patients with metastatic colorectal cancers is ... Her tumor is found to be wild-type for KRAS but harbors a mutation in BRAF at V600E ... to support the integration of EGFR, ERCC1, thymidylate synthase (TS), ...

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall ...

journals.plos.org/plosone/article?id=10.1371/journal.pone...

Name of journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 34313

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer

Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, George Peros, Stefanos Konstantoudakis, Danai Leventakou, Ioannis Panayiotides, Petros Karakitsos, Anna Koumarianou

Abstract

AIM

Match Overview

1	Internet 29 words crawled on 15-Sep-2016 ar.iiarjournals.org	1%
2	Internet 23 words crawled on 31-May-2017 repository.uobn.ru.nl	1%
3	Internet 21 words crawled on 04-Feb-2017 siop2016.kenes.com	<1%
4	Crossref 19 words Arrazubi, V., J. Suárez, D. Guerrero, M. Gómez, A. Viúdez, F. Arias, E. Balén, and R. Vera. "Prognostic significance	<1%
5	Crossref 19 words Sartore-Bianchi, Andrea, Salvatore Siena, Giuseppe Toni ni, Alberto Bardelli, and Daniele Santini. "Overcoming dy	<1%
6	Internet 17 words crawled on 02-Mar-2017 theoncologist.alphamedpress.org	<1%
7	Publications 15 words "Findings from F.A. Sinicrope et al Has Provided New I ..., ormation about Colon Cancer (Molecular Biomar", Canc	<1%
8	Crossref 14 words Christos S Karapetis. "Resistance to EGF receptor-tar... ted monoclonal antibodies in the management of advan	<1%



全部

新闻

图片

视频

购物

更多

设置

工具

找到约 31,900 条结果 (用时 0.51 秒)

Google 学术: Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer

... biomarkers in resected colon cancer: current status and ... - Tejpar - 被引用次数: 138

... prognostic and predictive markers in colorectal cancer - Walther - 被引用次数: 567

... diagnosis, prognosis and treatment of colorectal cancer - Coppède - 被引用次数: 86

Integrating anti-EGFR therapies in metastatic colorectal cancer

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者: S Haraldsdottir - 2013 - 被引用次数: 18 - 相关文章

2013年5月13日 - About 20% of patients present with metastatic colorectal cancer (mCRC) and untreated, for mutations in KRAS, BRAF and PIK3CA by direct sequencing as well as EGFR ... The KRAS mutation testing became a NCCN recommendation in November 2008 (19), Maughan TS, Adams RA, Smith CG, et al.

RAS testing in metastatic colorectal cancer: advances in Europe

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830882/> - 翻译此页

作者: JHJM Van Krieken - 2016 - 被引用次数: 7 - 相关文章

2015年11月16日 - The extension of markers from KRAS to RAS testing is the new ... Taken together, mutations in either KRAS or the closely related NRAS gene, but not in the BRAF gene, ... Prevalence of RAS mutations in patients with metastatic colorectal Integration of NGS technologies into the clinical setting has the ...

Biomarker Use in Colorectal Cancer Therapy - NCBI - NIH

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者: RK Kelley - 2011 - 被引用次数: 28 - 相关文章

KRAS mutational analysis for patients with metastatic colorectal cancers is Her tumor is found to be wild type for KRAS but harbors a mutation in BRAF at V600E ... to support the integration of EGFR

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 39,700 条结果 (用时 0.47 秒)

Google 学术 : Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer

... biomarkers in resected colon cancer: current status and ... - Tejpar - 被引用次数 : 138

... prognostic and predictive markers in colorectal cancer - Walther - 被引用次数 : 567

... diagnosis, prognosis and treatment of colorectal cancer - Coppedè - 被引用次数 : 86

Integrating anti-EGFR therapies in metastatic colorectal cancer

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者 : S Haraldsdottir - 2013 - 被引用次数 : 18 - 相关文章

2013年5月13日 - About 20% of patients present with metastatic colorectal cancer (mCRC) and untreated, for mutations in KRAS, BRAF and PIK3CA by direct sequencing as well as EGFR ... The KRAS mutation testing became a NCCN recommendation in November 2008 (19). Maughan TS, Adams RA, Smith CG, et al.

RAS testing in metastatic colorectal cancer: advances in Europe

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830882/> - 翻译此页

作者 : JHJM Van Krieken - 2016 - 被引用次数 : 7 - 相关文章

2015年11月16日 - The extension of markers from KRAS to RAS testing is the new ... Taken together, mutations in either KRAS or the closely related NRAS gene, but not in the BRAF gene, ... Prevalence of RAS mutations in patients with metastatic colorectal Integration of NGS technologies into the clinical setting has the ...

Biomarker Use in Colorectal Cancer Therapy - NCBI - NIH

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者 : RK Kelley - 2011 - 被引用次数 : 28 - 相关文章

KRAS mutational analysis for patients with metastatic colorectal cancers is Her tumor is found to be wild-type for KRAS but harbors a mutation in BRAF at V600E. ... to support the integration of EGFR, ERCC1, thymidylate synthase (TS), ...

ESMO Consensus Guidelines for the Management of Patients with